"Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) Resistant/Intolerant to Two or Three Approved Tyrosine Kinase Inhibitors (TKIs)(1)(")

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks.

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.

New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse.